Beyond Efficacy: The Real-World Challenges of GLP-1 Adherence
In the rapidly evolving landscape of metabolic health, the arrival of dual GIP/GLP-1 receptor agonists and potent GLP-1 analogues has marked a therapeutic water...
Jun 1, 2026
0 3
Science. Treatment. Real-world outcomes.
Stay Ahead of the GLP-1 Revolution
GLP-1 & Metabolic Health News delivers timely, evidence-based reporting on GLP-1 agonists, diabetes care, weight-management therapies, and metabolic research — clear, practical, and sourced from clinical experts.
Weekly briefings
Independently funded
Expert-vetted content
Latest Articles
New research, clinical updates, and patient stories
Fda Flags Novo Nordisk Over Glp-1 Safety Reporting Gaps
Fda Flags Novo Nordisk Over Glp-1 Safety Reporting Gaps On March 5, 2026, the U.S. Food and Drug Administration issued a formal warning letter to Novo Nordisk I...
May 29, 2026
0 4
REDEFINE-4: CagriSema Misses Non-Inferiority Against Tirzepatide
Novo Nordisk's Combination Therapy Delivers Strong Weight Loss, Yet Fails Head-to-Head Benchmark In a definitive test of mechanism-driven synergy, Novo Nordisk'...
May 25, 2026
0 6
Most Read
Popular guides and in-depth analyses
Oral Wegovy, higher‑dose semaglutide, and compounding limits reshape GLP‑1 market
Lede Two regulatory actions this winter — the FDA's approval of an oral Wegovy pill and a new higher‑dose semaglutide injection — plus a proposed FDA curtailing...
May 10, 2026
0 6
Tirzepatide’s CV findings and Medicare’s GLP‑1 Bridge
Lede Two developments this year are reshaping how clinicians, patients, and policymakers view next‑generation incretin therapies: the full report of the SURPASS...
May 11, 2026
0 7
Retatrutide’s 29% Weight Loss Marks the Rise of Triple Agonists
Setting the Clinical Benchmark for Obesity Pharmacotherapy In December 2025, Eli Lilly announced positive top-line results from its pivotal Phase 3 TRIUMPH-4 tr...
May 14, 2026
0 7
Explore Topics
Navigate by condition, treatment, or research area
GLP-1 Market Shifts Amid Patent Expiries and Trial Setbacks
The GLP‑1 landscape is undergoing a profound transformation as commercial realities collide with evolving clinical data. Early in 2026, Novo Nordisk issued a si...
May 13, 2026
0 8
Retatrutide’s 29% Weight Loss Marks the Rise of Triple Agonists
Setting the Clinical Benchmark for Obesity Pharmacotherapy In December 2025, Eli Lilly announced positive top-line results from its pivotal Phase 3 TRIUMPH-4 tr...
May 14, 2026
0 7
Tirzepatide’s CV findings and Medicare’s GLP‑1 Bridge
Lede Two developments this year are reshaping how clinicians, patients, and policymakers view next‑generation incretin therapies: the full report of the SURPASS...
May 11, 2026
0 7
Why GLP-1 & Metabolic Health News
Trusted, timely reporting on therapies and metabolism for clinicians, patients, and researchers — focused on evidence, context, and practical relevance.
Evidence-Based Reporting
Summaries and analyses grounded in peer-reviewed studies, clinical trials, and official guidelines.
Clinical Context
Actionable insights for clinicians on dosing, monitoring, side-effect management, and patient counseling.
Patient-Focused
Clear explanations, lived-experience perspectives, and resources to help patients navigate treatment choices.
Expert Contributors
Content informed by endocrinologists, researchers, pharmacists, and other specialists to ensure accuracy.
Policy & Access
Coverage of regulatory approvals, reimbursement developments, and market access that affect care delivery.
Newsroom Speed
Fast, careful coverage of breaking studies and guideline changes with follow-up analysis.
Free Access
Get our free newsletter
Weekly summaries, top stories, and practical tips delivered to your inbox at no cost.
Weekly research roundup
Treatment and safety highlights
Subscriber-only briefings
Stay Informed
Join clinicians, patients, and researchers who rely on concise, accurate coverage of GLP-1 therapies and metabolic health.
Subscribe FreeJoin the mailing list
Get new posts from GLP-1 & Metabolic Health News
Be the first to know when fresh articles are published.